328 related articles for article (PubMed ID: 31770057)
21. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.
Place AE; Stevenson KE; Vrooman LM; Harris MH; Hunt SK; O'Brien JE; Supko JG; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Welch JJ; Lipshultz SE; Kutok JL; Blonquist TM; Neuberg DS; Sallan SE; Silverman LB
Lancet Oncol; 2015 Dec; 16(16):1677-90. PubMed ID: 26549586
[TBL] [Abstract][Full Text] [Related]
22. The Characteristics and Risk Factors of Asparaginase-Associated Pancreatitis in Pediatric Acute Lymphoblastic Leukemia.
Kuo SH; Chen JS; Cheng CN; Lo HY; Chen WC; Lai FP; Yang YJ
Pancreas; 2022 Apr; 51(4):366-371. PubMed ID: 35695827
[TBL] [Abstract][Full Text] [Related]
23. Prolonged first-line PEG-asparaginase treatment in pediatric acute lymphoblastic leukemia in the NOPHO ALL2008 protocol-Pharmacokinetics and antibody formation.
Tram Henriksen L; Gottschalk Højfeldt S; Schmiegelow K; Frandsen TL; Skov Wehner P; Schrøder H; Klug Albertsen B;
Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28660740
[TBL] [Abstract][Full Text] [Related]
24. Can Machine Learning Models Predict Asparaginase-associated Pancreatitis in Childhood Acute Lymphoblastic Leukemia.
Nielsen RL; Wolthers BO; Helenius M; Albertsen BK; Clemmensen L; Nielsen K; Kanerva J; Niinimäki R; Frandsen TL; Attarbaschi A; Barzilai S; Colombini A; Escherich G; Aytan-Aktug D; Liu HC; Möricke A; Samarasinghe S; van der Sluis IM; Stanulla M; Tulstrup M; Yadav R; Zapotocka E; Schmiegelow K; Gupta R
J Pediatr Hematol Oncol; 2022 Apr; 44(3):e628-e636. PubMed ID: 35226426
[TBL] [Abstract][Full Text] [Related]
25. Successful Management of l-Asparaginase-Associated Pancreatitis With Octreotide and Pegylated Asparaginase in 2 Patients With Acute Lymphoblastic Leukemia: Is There a Different Rare Warning Sign of Hypoglycemia for l-Asparaginase-Associated Pancreatitis?
Aydin Köker S; Oymak Y; Demirağ B; Karapinar TH; Koker A; Genç S; Erdemir G; Vergin RC
Clin Ther; 2020 Apr; 42(4):e82-e86. PubMed ID: 32184014
[TBL] [Abstract][Full Text] [Related]
26. Clinical analysis of asparaginase-associated pancreatitis in children.
Du X; Liu Z; Jia X; Wen Y; Tang Y; Xu X; Jiang M
Pancreatology; 2022 Sep; 22(6):706-712. PubMed ID: 35718704
[TBL] [Abstract][Full Text] [Related]
27. Asparaginase-Associated Pancreatitis in Pediatric Patients with Acute Lymphoblastic Leukemia: Current Perspectives.
Gibson A; Hernandez C; Tejada FNH; Kawedia J; Rytting M; Cuglievan B
Paediatr Drugs; 2021 Sep; 23(5):457-463. PubMed ID: 34351604
[TBL] [Abstract][Full Text] [Related]
28. Octreotide therapy in asparaginase-associated pancreatitis in childhood acute lymphoblastic leukemia.
Wu SF; Chen AC; Peng CT; Wu KH
Pediatr Blood Cancer; 2008 Dec; 51(6):824-5. PubMed ID: 18726919
[TBL] [Abstract][Full Text] [Related]
29. Individualized Asparaginase Dosing in Childhood Acute Lymphoblastic Leukemia.
Kloos RQH; Pieters R; Jumelet FMV; de Groot-Kruseman HA; van den Bos C; van der Sluis IM
J Clin Oncol; 2020 Mar; 38(7):715-724. PubMed ID: 31922920
[TBL] [Abstract][Full Text] [Related]
30. [Experience in diagnosis and treatment of asparaginase-associated pancreatitis in children].
Chen Z; Li J
Zhonghua Er Ke Za Zhi; 2014 Nov; 52(11):854-8. PubMed ID: 25582474
[TBL] [Abstract][Full Text] [Related]
31. Pegaspargase-induced pancreatitis.
Alvarez OA; Zimmerman G
Med Pediatr Oncol; 2000 Mar; 34(3):200-5. PubMed ID: 10696127
[TBL] [Abstract][Full Text] [Related]
32. Clinical course and outcome in children with acute lymphoblastic leukemia and asparaginase-associated pancreatitis.
Kearney SL; Dahlberg SE; Levy DE; Voss SD; Sallan SE; Silverman LB
Pediatr Blood Cancer; 2009 Aug; 53(2):162-7. PubMed ID: 19405141
[TBL] [Abstract][Full Text] [Related]
33. Parents' and Adolescents' Preferences for Intensified or Reduced Treatment in Randomized Lymphoblastic Leukemia Trials.
Tulstrup M; Larsen HB; Castor A; Rossel P; Grell K; Heyman M; Abrahamsson J; Söderhäll S; Åsberg A; Jonsson OG; Vettenranta K; Frandsen TL; Albertsen BK; Schmiegelow K;
Pediatr Blood Cancer; 2016 May; 63(5):865-71. PubMed ID: 26717887
[TBL] [Abstract][Full Text] [Related]
34. A qualitative study of decision-making on Phase III randomized clinical trial participation in paediatric oncology: Adolescents' and parents' perspectives and preferences.
Ingersgaard MV; Tulstrup M; Schmiegelow K; Larsen HB
J Adv Nurs; 2018 Jan; 74(1):110-118. PubMed ID: 28771784
[TBL] [Abstract][Full Text] [Related]
35. Acid-suppressing Drugs and a Low 1 Level of Antithrombin as Risk Factors for L-Asparaginase-associated Pancreatitis: A Case-control Study in the Japan Association of Childhood Leukemia Study (JACLS).
Hashii Y; Yoshida M; Hara J; Nishimura S; Yumura-Yagi K; Horibe K; Nakahata T
J Pediatr Hematol Oncol; 2018 Jul; 40(5):374-378. PubMed ID: 29697579
[TBL] [Abstract][Full Text] [Related]
36. Obesity as a predictor of treatment-related toxicity in children with acute lymphoblastic leukaemia.
Egnell C; Heyman M; Jónsson ÓG; Raja RA; Niinimäki R; Albertsen BK; Schmiegelow K; Stabell N; Vaitkeviciene G; Lepik K; Harila-Saari A; Ranta S
Br J Haematol; 2022 Mar; 196(5):1239-1247. PubMed ID: 34726257
[TBL] [Abstract][Full Text] [Related]
37. Maintenance therapy and risk of osteonecrosis in children and young adults with acute lymphoblastic leukemia: a NOPHO ALL2008 sub-study.
Toksvang LN; Andrés-Jensen L; Rank CU; Niinimäki R; Nersting J; Nielsen SN; Mogensen SS; Harila-Saari A; Abrahamsson J; Joelsson J; Overgaard UM; Quist-Paulsen P; Griškevičius L; Jónsson ÓG; Vaitkevičienė G; Frandsen TL; Toft N; Grell K; Schmiegelow K
Cancer Chemother Pharmacol; 2021 Nov; 88(5):911-917. PubMed ID: 34145469
[TBL] [Abstract][Full Text] [Related]
38. [Efficacy observation of polyethylene glycol conjugated asparaginase for induction treatment of children with newly diagnosed acute lymphoblastic leukemia].
Liu F; Wan Y; Chang L; Guo Y; Yang W; Wang S; Chen X; Liu T; Ruan M; Zhang L; Liu X; Zou Y; Chen Y; Zhu X
Zhonghua Er Ke Za Zhi; 2014 Mar; 52(3):215-7. PubMed ID: 24824393
[TBL] [Abstract][Full Text] [Related]
39. Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia.
Silverman LB; Supko JG; Stevenson KE; Woodward C; Vrooman LM; Neuberg DS; Asselin BL; Athale UH; Clavell L; Cole PD; Kelly KM; Laverdière C; Michon B; Schorin M; Schwartz CL; O'Brien JE; Cohen HJ; Sallan SE
Blood; 2010 Feb; 115(7):1351-3. PubMed ID: 20007809
[TBL] [Abstract][Full Text] [Related]
40. Clinical and demographic factors contributing to asparaginase-associated toxicities in children with acute lymphoblastic leukemia.
Dharia P; Swartz MD; Bernhardt MB; Chen H; Gramatges MM; Lupo PJ; Brown AL; Scheurer ME
Leuk Lymphoma; 2022 Dec; 63(12):2948-2954. PubMed ID: 35895075
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
